1Drugeon HB, Juvin ME, Bryskier. Relative potential for selection of fluoroquinolone-resistant streptoccus pneumoniae strains by levofloxacin: Comparison with Ciprofloxacin, sparfloxacin and ofloxacin [J]. J Antimicrob Chemother, 1999, 43 (Suppl)C55.
2Sullivan J G, McElroy A, Honsinger RW, et al. A double-blind, randomized study of Safety and efficacy treating community acquired pneumonia with once-daily gatifloxacin vs once-daily levofloxacin [J]. J Respir Dis,1999, 20 (Suppl) :49.
3Forgarty C, Dowell ME, Ellison WT, et al. A prospective, randomized, double-blind study treating community-acquired pneumonia in hospitalized patients Gatifloxacin VS Ceftriaxone/Clarithromycin [J]. J Respir Dis, 1999, 20 (Suppl): 60.
4Heffelfingers JD, Dowell SF, Jorgensen JH, et al. Management of community-acquired pneumonia in the era of pneumococcal resistance. A report from the drugresistant Streptococcus pneumoniae therapeutic working group [J]. Arch Intern Med, 2000, 160 (10) :13
5Bristor-Myer Squibb. Gatifloxacin (Tequin) :An advanced generation quinolone for the treatment of selected infectious diseases [M] .Glenview: Physicians Scientists Publishing CO, INC, 2000. 47.
6Wish R, Honeybourne D. Pharmacokinetics and pharmacodynamics of fluoroquinolones in the respiratory tract[J]. European Respir J, 1999, 14 ( 1 ): 221.
7Ball P, Wilson R, Mandell L, et al. Efficacy of gemifloxacin in acute exacerbations of chronic bronchitis: a randomized, double-blind comparison with trovafloxacin[J]. J Chemother 2001,13 (3):288.
8Tillotson G, Zhao X, Drilica K. Fluoroquinolones as pneumococcal therapy: Closing the barn door before the horse escapes [J]. The Lancet infections Disea, 2001, 1(3): 145.
9Read RC, Morrissey I, Ambler J E, et al. Clinician′s manual on respiratory tract infections and fluoroquinolones [M] .London: Science Press Ltd, 2000.29.
1[1]Morrissey I, George JT. Purification of pneumococcal type Ⅱ topoisomerases and inhibition by gemifloxacin and other quinolones. [J]. JAntimicrob Chemother, 2000, 45(Suppl S1):101
2[2]Hardy D, Amsterdam D, Mandell LA, et al. Comparative in vitro activities of ciprofloxacin, gemifloxacin, grepafloxacin, moxifloxacin, ofloxacin, sparfloxacin, trovafloxacin, and other antimicrobial agents against bloodstream isolates of gram-positive cocci. [J]. Antimicrob Agents Chemother, 2000, 44(2):802
3[3]Cormican MG, Jones RN. Antimicrobial activity and spectrum of LB20304, a novel fluoronaphyridone. [J]. Antimicrob Agents Chemother, 1997, 41(1): 200
4[4]Goldstein EJC, Citron DM, Warren Y, et al. In vitro activity of gemifloxacin (SB 265805) against anaerobes. [J]. Anfimicrob Agents Chemother, 1999, 43(9): 2231-2235
5[5]Dubois J, St-Pierre C. Comparative in vitro potency and post-antibiotic effect of gemifloxacin against Legionella spp. [J]. J Antimicrob Chemother, 2000, 45 (suppl. S1): 41
6[6]Roblin PM, Reznik T, Kutlin A, et al. In vitro activities of gemifloxacin (SB 265805, LB20304) against recent chnical isolates of Chlamydia pneumoniae. [J]. Antimicrob Agents Chemother, 1999, 43(11):2806
7[7]Oh JI, Paek KS, Ahn MJ, et al. In vitro and in vivo evaluations of LB20304, a new fluoronaphthyridone. [J]. Antimicrob Agents Chemother, 1996, 40(6): 156 4
8[8]Berry V, Page R, Satterfield J, et al. Comparative in vivo activity of gemifloxacin in a rat model of respiratory tract infection. [J]. J Antimicrob Chemother, 2000,45(Suppl S1):79
9[9]Berry V, Page R, Satterfield J, et al. Comparative efficacy of gemifloxacinin experimental modes of pyelonephritis and wound infection. [J].J Antimicrob chemother, 2000,45(suppl s1): 87
10[10]Dubois J, St-Pierre C. Comparative in vitro activity and post-antibiot ic effect of gemifloxacin against Legionella spp. [ J]. J Antimicrob Chemother, 2000, 45 (Suppl S1): 41
